Thursday’s trading session witnesses notable swings among stocks across the board, with significant moves in both the mega-cap and large-cap categories. Oracle Corp (NYSE:) and Dell Inc (NYSE:) are among the stocks experiencing a decline, while MicroStrategy Inc (NASDAQ:) is rising. Here’s a look at some of today’s top stock movers, ranging from mega caps to small caps.
Mega-Cap Movers (market cap $200 billion+):
- Oracle Corp (ORCL): -4.03%
- Salesforce Com (NYSE:): -3.84%
- Avago Technologies (NASDAQ:): -3.08%
- Servicenow Inc (NYSE:): -2.68%
- Adobe Sys Inc (NASDAQ:): -2.21%
Large-cap stock movers (market cap $10 billion-$200 billion):
- Dell Inc (DELL): -12.25%
- Hewlett Pack (NYSE:): HP shares have been downgraded to Hold by HSBC due to weak 1Q25 outlook and rising commodity costs; -11.36%
- MicroStrategy Inc (MSTR): +9.94%
- Autodesk Inc (NASDAQ:): -8.59%
- Nutanix Inc (NASDAQ:): Nutanix to Present at Upcoming Investor Conference; -7.81%
- BeiGene (NASDAQ:): +7.31%
- Reinventing Technology Partners Y (AUR): +7.27%
- Li Auto Inc (NASDAQ:): American Lithium reports annual general and special meeting results; +6.78%
- IBIT NASDAQ (IBIT): +6.44%
- FBTC NYSE (FBTC): +6.37%
Mid-cap stock movers (market cap $2 billion-$10 billion):
- SVF Investment 3 (SYM): -35.87%
- Iris energy (IREN): +29.71%
- Arrowhead Research Corp (NASDAQ:): +24.23%
- Urban outfitters (NASDAQ:): +18.31%
- Hut 8 HP (HUT): +16.5%
- HCM takeover (MRNO): +16.17%
- Acquisition of Good Works (CIFR): +14.56%
- MSTU (MSTU): +13.93%
Small company stock movers (market cap $300 million – $2 billion):
- Advanced Photonix Inc (API): +33.97%
- ETHU (ETHU): +18.79%
- Golden Bull (BTBT): +18.45%
- Fate Therap (NASDAQ:): +18.28%
- Kingsoft Cloud Holdings Ltd (KC): +17.42%
- Immunome Inc (NASDAQ:): +16.83%
- Wowo Ltd (MFH): -16.32%
- Semler Scientific (NASDAQ:): +16.06%
- Applied Therapeutics Inc (NASDAQ:): FDA Denies Approval for Applied Therapeutics’ Galactosemia Drug; -16.06%
For real-time, market-moving news, join Investing Pro.
This article was produced with the support of AI and reviewed by an editor. For more information see our General Terms and Conditions.
